Haemodynamic Changes With Different Noninvasive Respiratory Modes for Primary Respiratory Support in Preterm Neonates
NCT ID: NCT06737003
Last Updated: 2024-12-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
90 participants
INTERVENTIONAL
2021-09-01
2023-09-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* This study included spontaneously breathing preterm neonates with gestational age equal to or less than 35 weeks in need for noninvasive respiratory support during their first 3 days of life for primary treatment of respiration distress syndrome.
* Diagnosis of Respiratory distress syndrome (RDS) was done by clinical examination, including signs of respiratory distress, venous blood gases showing hypoxemia and hypercapnia, and chest X-ray showing diffuse atelectasis, classically described as a ground glass appearance .
* Neonates with upper or lower airway anomalies or significant congenital anomalies were excluded from the study.
* Out of 105 neonates assessed for eligibility, 15 were excluded; 10 guardians declined to participate, and 5 didn't meet the inclusion criteria. Thus, 90 neonates were enrolled.
Out of 105 preterm neonates assessed for eligibility, 15 neonates were excluded: 3 had confirmed congenital heart disease, 2 had cleft palate, and 10 parents/guardians refused to consent . 90 neonates were randomly allocated to the three noninvasive modes using a computer-based randomization program, with 30 neonates in each group. Sealed envelopes containing treatment assignments were opened in a sequential manner. No crossover was allowed in the study.
NHFOV group: was delivered by SLE 6000 device (Wipro GE Healthcare Private Limited, Bengaluru, Karnataka). Settings: amplitude range (20:35) cm H2O, frequency range (8-12) HZ, Mean airway pressure (MAP) range (6:10) cm H2O, and Inspiration :Expiration (I:E) ratio 1:1 to 1:2 in case of air trapping, using nasal prongs .
Vapotherm Group: was delivered by Vapotherm Device (Vapotherm, INC, USA). Settings: flow rate 4-6 L/min, with temperature 36-37 °C and Fraction of inspired oxygen(FiO2) titrated as needed to achieve target Saturation of peripheral oxygen (SpO2) (90% to 94%) using soft nasal cannula interface .
Nasal CPAP Group: was delivered by MEDIN CNO device (Medin Medical Innovations GmbH, Olching, Germany). Settings: pressure ranging from 5 to 8 cm H2O to maintain SpO2 from 90% to 94% using bi-nasal prongs.
Clinical examination and routine neonatal care:
Newborns included in the study were subjected to detailed perinatal and family history, thorough clinical examination, and standard neonatal care practices. Each infant's clinical condition, vital data, daily weight, and total enteral and parenteral fluid intake were monitored and recorded.
* The gestational age was assessed based on the mother's last menstrual period and confirmed by using the modified Ballard score .
* APGAR score and Silverman score were recorded .
* Oxygen Saturation Index (OSI) was calculated according to the equation of OSI = MAP X FiO2 X100/SPO2 .
* Daily inspection of infants' nostrils and nasal trauma score was graded as follows: Grade I: persistent hyperemia; Grade II: superficial ulceration; and Grade III: necrosis and tissue loss .
* Feeding assessment: A nasogastric tube was inserted for all included neonates on noninvasive respiratory support; feeding increment was handled in accordance with NICU protocol of Ain Shams University.
Respiratory management:
-Criteria for starting noninvasive ventilation according to NICU protocol of Ain Shams University, including:
1. Mild to moderate respiratory distress; defined as Silverman score \<6, FIO2≤30% to maintain target saturation
2. Mild to moderate respiratory acidosis Partial pressure of carbon dioxide (PCO2)\<65 mmHg with PH \> 7.2.
3. Mild to moderate hypoxemia (FiO2 less than or equal 30% to maintain SPO2 (90-94%)
4. No more than one apneic episode that necessitates intermittent positive pressure breathing per day, or six or more apneic episodes that require stimulation in arow.
Criteria for failure of noninvasive ventilation and shifting to invasive ventilation with surfactant administration according to NICU protocol of Ain Shams University, including:
1. Severe respiratory distress characterized by retractions, moaning sounds, or nasal flaring, defined as a Silverman score \>6 .
2. Severe respiratory acidosis (PaCO2 ≥ 65 mmHg with pH ≤ 7.20),
3. Hypoxemia (FiO2 \> 30% to maintain SpO2 90% to 94%) while the patient is receiving maximal noninvasive settings
4. More than one apneic episode that necessitates intermittent positive pressure breathing per day, or six or more apneic episodes that require stimulation in arow
5. An immediate requirement for intubation as decided by the treating physician.
Criteria for weaning off non-invasive ventilation (success of non-invasive ventilation) in this study were based on stability criteria.
1. For CPAP Positive end expiratory pressure (PEEP): 5-6 cm H2O / FiO2 \<40% to maintain target saturation / Respiratory rate (RR) \<60 breaths per minute / no significant chest retraction / not currently treated for Patent ductus arteriosus (PDA) and tolerating time off CPAP up to 15 minutes and less than 3 episodes of self-reverting apnea per day .
2. For Vapotherm Weaning oxygen first, then flow reduced by 1 liter/minute each time until 2-4 L/minutes .
3. For NHFOV FiO2 weaned first by 3-5% while maintaining target saturation until it reaches 30%, then mean airway pressure tapered every 6 h by 1 cm until 6 cm H2O .
* All neonates in this study received caffeine citrate for apnea of prematurity and as a prophylactic treatment for chronic lung disease. Manufactured by Chiesi Pharmaceuticals, Parma, Italy. The initial loading dose was 20 mg/kg, and the maintenance dose was 5-10 mg/kg per day.
Laboratory analysis Laboratory investigations performed included baseline complete blood count with differential leukocyte using Coulter Counter GEN-S (Coulter Corporation, IN), and a high-sensitivity C-reactive protein measurement using a quantitative assay by Latex agglutination slide test, spin react, and Spain (Omega Diagnostics LTD, UK); the detection limit for CRP was 6 mg/L . Blood gases were analyzed using ABL 5 blood gas analyzer (Diamond Diagnostics, USA) at baseline, following initiation of noninvasive support and were repeated as clinically indicated.
Radiological analysis:
A- chest x-ray was done initially for the diagnosis of RDS and repeated as clinically indicated.
B-Abdominal X-ray was done when feeding intolerance and necrotizing enterocolitis (NEC) were suspected.
• Hemodynamic assessment: Was done twice, one while still on non-invasive ventilation just one hour before weaning and one hour after being weaned off the allocated device.Pre- and post-weaning studies were done by the same operator to minimize inter-observer variability.
During examination, neonates were in a resting state and lying in a supine position with temperature maintained, and the examinations were done within 15 minutes. Environmental light intensity was low and constant. Phototherapy was suspended during measurements. To avoid crying episodes and stress conditions, gentle handling consisting of delicate touching and calm voice tones were applied, along with pacifiers and stimulation of non-nutritional sucking in order to pacify the baby in each mode of noninvasive ventilation.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
NHFOV group
Nasal high frequency oscillatory ventilation (NHFOV) will be delivered by; SLE 6000 device, Wipro GE Healthcare Private Limited, Bengaluru, Karnataka. Amplitude range (20:35), frequency range (8-12)HZ, Mean air way pressure(MAP) range (6: 10) cmH2O and Inspiration :Expiration (I:E) ratio 1:1 may change to 1:2 in case of air trapping .
Nasal high frequency oscillatory ventilation
NHFOV was administered using the SLE 6000 device manufactured by Wipro GE Healthcare Private Limited in Bengaluru, Karnataka. The initial amplitude was set at 25 cm H2O and adjusted to a maximum of 35 cm H2O based on clinical response. The frequency was set at 12 Hz. The mean airway pressure (MAP) was initiated at 6 cmH2O and titrated up to 10 cmH2O based on clinical assessment. The I:E ratio was maintained between 1:1 to 1:2 in cases of air trapping, using nasal prongs •
Vapotherm group
Vapotherm will be delivered by; Vapotherm device,Vapotherm,INC,USA. The recommended starting flow rate is 4-6 L/min. To be titrated to clinical effect to maximum of 8 L/min as needed,with temperature 36-37°C andFraction of inspired oxygen (FiO2) titrated as needed to achieve target Saturation of peripheral oxygen (SpO2)(90% to 94%).
Vapotherm Group
The Hi-VNI Vapotherm was administered using the Vapotherm device, manufactured by Vapotherm, INC, USA. Initially, the flow rate was set at 4 L/min and adjusted accordingly to achieve the desired clinical outcome, with a maximum flow rate of 8 L/min when necessary. The temperature was maintained at 36-37°C, and the FiO2 was adjusted as required to attain the target SpO2 range of 90% to 94%، using soft nasal cannula interface
Standard noninvasive mechanical ventilation group (CPAP)
CPAP will be delivered by; MEDIN CNO device, medin Medical Innovations GmbH, Olching, Germany . Pressure ranging from 5 to 8 cm H2O,to maintain SpO2 from 90% to 94%.
Nasal CPAP Group
CPAP therapy was administered using the MEDIN CNO device, developed by medin Medical Innovations GmbH in Olching, Germany. The initial pressure was set at 5 cmH2O and adjusted accordingly to achieve the desired clinical outcome, with a maximum pressure of 8 cmH2O. This approach aimed to maintain the target oxygen saturation (SpO2) levels between 90% and 94%، using bi-nasal with midline prongs
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nasal high frequency oscillatory ventilation
NHFOV was administered using the SLE 6000 device manufactured by Wipro GE Healthcare Private Limited in Bengaluru, Karnataka. The initial amplitude was set at 25 cm H2O and adjusted to a maximum of 35 cm H2O based on clinical response. The frequency was set at 12 Hz. The mean airway pressure (MAP) was initiated at 6 cmH2O and titrated up to 10 cmH2O based on clinical assessment. The I:E ratio was maintained between 1:1 to 1:2 in cases of air trapping, using nasal prongs •
Vapotherm Group
The Hi-VNI Vapotherm was administered using the Vapotherm device, manufactured by Vapotherm, INC, USA. Initially, the flow rate was set at 4 L/min and adjusted accordingly to achieve the desired clinical outcome, with a maximum flow rate of 8 L/min when necessary. The temperature was maintained at 36-37°C, and the FiO2 was adjusted as required to attain the target SpO2 range of 90% to 94%، using soft nasal cannula interface
Nasal CPAP Group
CPAP therapy was administered using the MEDIN CNO device, developed by medin Medical Innovations GmbH in Olching, Germany. The initial pressure was set at 5 cmH2O and adjusted accordingly to achieve the desired clinical outcome, with a maximum pressure of 8 cmH2O. This approach aimed to maintain the target oxygen saturation (SpO2) levels between 90% and 94%، using bi-nasal with midline prongs
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patients with significant congenital anomalies including cardiac, abdominal or respiratory.
25 Weeks
34 Weeks
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ain Shams University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Rania Ali El-Farrash
Professor of Pediatrics
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Rania el farrash
Role: STUDY_CHAIR
Ain Shams University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ainshams university
Cairo, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Hemodynamic ,noninvasive
Identifier Type: -
Identifier Source: org_study_id